Financials in USD. Standardized financial statements.
A compact view of how Arcutis Biotherapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $376.07M | $196.54M | $59.61M | $3.69M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +91.3% | +229.7% | +1517.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $36.70M | $19.13M | $4.99M | $754,000 | $763,000 | $455,000 | $195,000 | $0 | $0 |
| Gross Profit? | $339.38M | $177.41M | $54.62M | $2.93M | -$763,000 | -$455,000 | -$195,000 | $0 | $0 |
| Gross Margin? | +90.2% | +90.3% | +91.6% | +79.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $351.60M | $305.81M | $295.72M | $304.56M | $205.77M | $136.19M | $42.94M | $19.73M | $4.11M |
| Operating Income? | -$12.23M | -$128.40M | -$241.10M | -$301.63M | -$206.53M | -$136.65M | -$43.13M | -$19.73M | -$4.11M |
| EBITDA? | $2.48M | -$109.63M | -$227.43M | -$294.55M | -$205.59M | -$135.22M | -$41.80M | $480,000 | -$872,000 |
| Income Before Tax | -$14.97M | -$139.39M | -$259.03M | -$311.46M | -$206.36M | -$135.68M | -$42.00M | -$19.25M | -$4.98M |
| Income Tax Expense | $1.17M | $647,000 | $3.11M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$16.14M | -$140.04M | -$262.14M | -$311.46M | -$206.36M | -$135.68M | -$42.00M | -$19.25M | -$4.98M |
| EPS? | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.17 | $-3.80 | $-1.10 | $-0.53 | $-4.71 |
| Diluted EPS? | $-0.13 | $-1.16 | $-3.78 | $-5.66 | $-4.17 | $-3.80 | $-1.10 | $-0.53 | $-4.71 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality